- A pair of influential senators are seeking answers about the steep cost of the hepatitis C drug Sovaldi. Sens. Ron Wyden (D-Ore.), chairman of the Finance Committee, and Chuck Grassley (R-Iowa), the ranking minority member of the Judiciary Committee, sent a letter last week to the chairman and CEO of Sovaldi manufacturer Gilead Sciences with questions about how the drug's price was determined. The senators also are seeking detailed information about the company's November 2011 purchase of Pharmasset, the original developer of Sovaldi.
Lawmakers probe Sovaldi pricing, and other briefs
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.